Regulatory B‐cell compartment in transfused alloimmunized and non‐alloimmunized patients with sickle cell disease. Issue 9 (20th June 2013)

• Record Type: Journal Article
• Authors: Bao, Weili; Zhong, Hui; Manwani, Deepa; Vasovic, Ljiljana; Uehlinger, Joan; Lee, Margaret T.; Sheth, Sujit; Shi, Patricia; Yazdanbakhsh, Karina
• Is Part Of: American journal of hematology. Volume 88:Issue 9(2013:Sep.)
• Page Start: 736
• Page End: 740
• Publication Date: 2013-06-20
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23488
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Transfusion therapy is a life‐sustaining treatment for patients with sickle cell disease (SCD), but can cause serious complications including alloimmunization. We previously reported diminished regulatory T cells (Tregs) and skewed Th2 responses in alloimmunized SCD patients. We hypothesized that the B cell regulatory (Breg) compartment, which controls Treg and Th differentiation, may also be compromised in allosensitized SCD patients. Phenotypically, we did not find differences in the frequency or numbers of CD24^hiCD38^hi and CD24^hiCD27⁺ B cell subsets, both previously identified as human Bregs, between alloimmunized and non‐alloimmunized SCD patients on regular transfusions. However, at the functional level, CD19+ B cells from alloimmunized SCD patients expressed lower levels of IL‐10 following stimulation as compared with non‐alloimmunized patients (<italic>P</italic> &lt; 0.05), and had reduced ability in inhibiting autologous CD14+ monocyte TNF‐α expression (<italic>P</italic> &lt; 0.05). These findings suggest that Bregs from alloimmunized and non‐alloimmunized SCD patients differ in their ability to produce IL‐10 and dampen monocyte activation, all consistent with an altered immunoregulatory state in alloimmunized SCD patients. Am. J. Hematol. 88:736–740, 2013. © 2013 Wiley Periodicals, Inc.</p> </abstract>